7月 2026
- 首頁
- VectorY
7月 2026VectorY的市場佔有率分析
Financing led by founding investor Forbion and a leading global investment firm, and joined by BioGeneration Ventures (BGV) and Eli Lilly & Company Proceeds to establish pre-clinical proof of concept for vectorized antibodies in ALS and Alzheimer’s and to further expand the team Compa
VectorY(包含公司地區)
查看更多網站流量與參與度資訊- vectorytx.com
VectorY截至 7月 2026 的總收入為 2M - 5M
VectorY 熱門網域產生的總收入
VectorY 熱門網域 3 年內的總收入
VectorY 熱門網域的總收入
VectorY的熱門網域總造訪量
了解VectorY市場觸達率與潛在市場影響力。
過去 3 個月的訪問總量
子公司細目
VectorY的熱門網域平均造訪時長
分析VectorY參與度指標。
過去 3 個月平均造訪時長
子公司細目
VectorY的熱門網域平均頁面瀏覽量
了解VectorY如何保持使用者的參與度、培養其興趣,並鼓勵他們採取下一步。
過去 3 個月平均頁面瀏覽量
子公司細目
想要取得更深入的流量洞見?
篩選超過 2,030 萬家線上企業。在流量激增、開始或停止使用技術或獲得正面評價時,發現新的潛在客戶。
新聞與訊號來自VectorY
透過 Similarweb 銷售訊號提醒,每當目標受眾出現新的機會或威脅時,你就會收到每日更新的已識別購買訊號。
新聞Unlearn partnered with vectorytx.com on Feb 12th '26.SAN FRANCISCO, CA, February 12, 2026 (Newswire.com) - Unlearn, a leader in AI solutions for clinical trials, today announced it is partnering with VectorY Therapeutics, a biotechnology company developing vectorized antibody therapies, to support VectorY's PIONEER-ALS Phase 1/2 clinical study by using digital twins as patient-level external comparators for exploratory data analysis.
2月 12, 2026閱讀更多
新聞vectorytx.com is developing vectorized antibody therapies for three neurodegenerative programs.VectorY Therapeutics partnered with Shape Therapeutics to develop vectorized antibody therapies for three neurodegenerative programs using Shape's engineered AAV5-derived SHP-DB1 capsid, designed for deep-brain penetration and reduced toxicity.
12月 16, 2025閱讀更多
新聞vectorytx.com attended event European Society of Gene & Cell Therapy (ESGCT) Conference on Oct 2nd '25.Amsterdam, the Netherlands, Boston, Massachusetts, and Seattle, Washington - October 2, 2025 - VectorY will be present at the European Society of Gene & Cell Therapy (ESGCT) Conference in Seville on 7 - 10 Oct, 2025.
10月 2, 2025閱讀更多
查看所有VectorY信號
讓銷售團隊專注於最有希望的機會。透過安排機會的優先順序,並在正確的時間參與,您可將工作最佳化,並完成更多交易。
